Bringing the fundamentals into focus…
Back to Relmada Therapeutics, Inc.
How Relmada Therapeutics, Inc. stacks up
RLMD · against 436 other Healthcare companies of similar size
Valuation
33/ 100
Below the middle of the pack.
Ranked #246 of 437 · scores higher than 41% of peers
Bars: peers in each 10-point band of the valuation score36 peers with a valuation score of 30–39, including RLMD · Click a bar to see the companies
Why valuation scores 33?
Weighted metrics compared with all Healthcare companies.Mainly because of its earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Earnings yield: -21.5% vs peer median 1.5%
- Negative (a loss or cash outflow), so it counts as zero whatever the share price. Free cash flow yield: -10.1% vs peer median 0.0%
- EBITDA yield is not reported, so it is left out of the score.
Metric by metric
Position: dot = RLMD, ranked from the worst peer (left) to the best (right); tick = middle, shaded = middle half of peers.| Metric | RLMD | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 423 reported | -21.5% | 0.4% | 15% | 30% | |
| EBITDA yieldHigher is better · 442 reported | Not reported | 3.2% | — | — | 50% |
| Free cash flow yieldHigher is better · 200 reported | -10.1% | -7.6% | 42% | 20% | |
| Book yieldHigher is better · 433 reported | 45.3% | 49.3% | 45% | Context only |
A metric that is not reported is left out of the score; the other weights are rescaled.
Ranking by valuation score
Top 5 and the companies ranked around RLMDScores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score